Innate Pharma S.A. IPHYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 91.05% | 107.27% | -71.85% | -72.58% | -78.75% |
| Total Other Revenue | -18.11% | -11.17% | -4.04% | -6.55% | -17.02% |
| Total Revenue | 19.41% | 29.55% | -41.79% | -43.31% | -58.49% |
| Cost of Revenue | -15.71% | -8.56% | 10.14% | 7.25% | -25.58% |
| Gross Profit | 26.61% | 20.38% | -36.83% | -33.25% | 1.31% |
| SG&A Expenses | -18.19% | -11.24% | 3.74% | 1.02% | 7.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.51% | -9.42% | 8.18% | 5.34% | -17.39% |
| Operating Income | 23.38% | 16.87% | -23.56% | -20.32% | -1.89% |
| Income Before Tax | 5.78% | -2.22% | -23.02% | -19.80% | 9.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.78% | -2.22% | -23.02% | -19.80% | 9.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.78% | -2.22% | -23.02% | -19.80% | 9.12% |
| EBIT | 23.38% | 16.87% | -23.56% | -20.32% | -1.89% |
| EBITDA | 23.47% | 16.98% | -24.84% | -21.57% | -3.37% |
| EPS Basic | 12.71% | 5.34% | -8.33% | -5.50% | 15.47% |
| Normalized Basic EPS | 12.74% | 5.20% | -8.39% | -5.45% | 15.44% |
| EPS Diluted | 13.95% | 6.54% | -8.33% | -5.50% | 14.93% |
| Normalized Diluted EPS | 12.74% | 5.20% | -8.39% | -5.45% | 15.44% |
| Average Basic Shares Outstanding | 7.93% | 7.93% | 13.56% | 13.56% | 7.50% |
| Average Diluted Shares Outstanding | 7.93% | 7.93% | 13.56% | 13.56% | 7.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |